Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
On Tuesday, Amgen Inc. (NASDAQ:AMGN) reported second-quarter sales of $8.39 billion, up 20% year over year and beating the consensus of $8.33 billion.
週二，安進股份有限公司（納斯達克：AMGN）報告了第二季度銷售額爲839億美元，同比增長20％，超過了833億美元的共識。
Product sales grew 20%, driven by 26% volume growth, partially offset by a 3% lower net selling price.
產品銷售額增長20％，其中成交量增長26％，部分抵消3％的淨銷售價格下降。
Excluding sales from the Horizon Therapeutics acquisition, product sales grew 5%, driven by 10% volume growth.
除了Horizon Therapeutics收購的銷售額，產品銷售額增長了5％，成交量增長了10％。
Twelve products delivered at least double-digit sales growth in the second quarter, including Prolia (denosumab), Evenity (romosozumab), Repatha (evolocumab), Tezspire (tezepelumab), Blincyto (blinatumomab), and Tavneos (avacopan).
第二季度12款產品的銷售額增長率均達到兩位數，包括普羅利亞（去甲肝納珠單抗），Evenity（羅莫珊單抗），Repatha（依倫肝素酯） ），Tezspire（特色佩盧單抗），Blincyto（布利那單抗）和Tavneos（avacopan）等。
Related: Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal.
相關：安進通過280億美元的Horizon收購尋求擴大美國自身免疫性疾病藥物的批准。
The company reported adjusted EPS of $4.97, missing the consensus of $5.01.
公司報告的調整後每股收益爲4.97美元，低於5.01美元的共識。
Guidance: Amgen expects fiscal year 2024 adjusted EPS of $19.10-$20.10 compared to the consensus of $17.87.
預測：安進預計2024財年調整後每股收益爲19.10-20.10美元，而共識爲17.87美元。
The company forecasts 2024 revenues of $32.8 billion-$33.8 billion versus the consensus of $30.3 billion.
公司預測其2024年收入爲328億-338億美元，而共識爲303億美元。
William Blair sees a significant upside for Amgen stock if the Phase 2 MariTide results demonstrate clear differentiation later this year.
威廉·布萊爾（William Blair）認爲，如果第二階段MariTide的結果在今年晚些時候明顯有所區別，則安進股票的上漲空間將顯著增加。
A Phase 2 study of MariTide is ongoing in adults with overweight or obesity with or without type 2 diabetes mellitus. Topline data are anticipated in late 2024.
MariTide的第二階段研究正在進行中，對象是體重超標或肥胖的成年人，伴有或不伴有2型糖尿病。頂線數據預計在2024年年底發佈。
A Phase 2 trial investigating MariTide for type 2 diabetes in patients with and without obesity is planned to initiate in late 2024.
計劃於2024年底開始進行MariTide治療2型糖尿病患者（有或沒有肥胖症）的第二階段試驗。
With shares trading at roughly 17 times the updated 2024 EPS estimate of $19.25, the analyst says there is meaningful room for multiple expansions with continued investor enthusiasm for MariTide's prospects.
該分析師表示，隨着股票交易價格約爲更新後2024年每股收益預測的17倍25美元，如果繼續對MariTide的前景感到熱情，將有顯著的多重擴張空間。
"Additional pipeline assets, including Imdelltra and rocatinlimab, also have blockbuster potential, and we believe additional Phase 3 readouts with Uplinza expected in the second half of this year have the potential to support the blockbuster potential of that franchise as well," the analyst added.
該分析師補充說：“其他的管道資產，包括Imdelltra和rocatinlimab，也具有億美元的潛力，而我們認爲Uplinza的其他第三階段讀數有望在今年下半年支持該公司積木類的潛力。”。
Amgen faces near-term challenges with legacy products, such as the upcoming biosimilar launch to Prolia and Xgeva in May 2025, and struggles to expand market share with its biosimilars. However, the analyst notes that clinical developments over the next 6 to 12 months offer significant reasons for investor optimism regarding the company's long-term growth prospects.
安進面臨着傳統產品的短期挑戰，例如即將推出Prolia和Xgeva的生物類似物，並且在其生物類似物中推廣市場份額。然而，該分析師指出，在未來6至12個月內的臨床發展中，投資者對公司長期增長前景的樂觀情緒提供了重要的原因。
William Blair reiterates the Outperform rating.
William Blair重申Outperform評級。
Price Action: AMGN stock was down 4.99% at $312.80 at the last check on Wednesday.
價格行動：最後一次交易時，AMGN股票下跌4.99％，至312.8美元。
- CVS Health Reports Mixed Q2 Earnings, Lowers 2024 Outlook, Reshuffles Segment Management.
- 西維斯健康公佈Q2業績，業績表現不俗，2024年前景調低，重組段領導團隊。
Photo via Shutterstock
圖片來自shutterstock。